Nox Health has acquired Somryst, the first FDA-cleared Prescription Digital Therapeutic (PDT) that delivers effective, first-line treatment for adults with chronic insomnia. This acquisition deepens the Nox value-based healthcare programs, as it seeks to reframe sleep as a critical and powerful intervention strategy for chronic health conditions management.
“The acquisition of Somryst aligns seamlessly with Nox's mission of promoting science-based solutions that address chronic diseases through sleep care management. As an outcomes-driven company with ten years of real-world data, it was important for us to find a solution with equal depth in validation and outcomes data, thereby setting it apart from other CBT-I solutions,” said Sigurjon Kristjansson, CEO of Nox Health.
Insomnia is a highly prevalent complaint associated with significant adverse health outcomes. CBT-I is recognized as the treatment of choice, but it remains underutilized due to lack of therapists with adequate CBT-I expertise. By delivering CBT-I via a mobile application, Somryst offers health care providers a novel treatment delivery modality to enhance the treatment of chronic insomnia for patients who lack access to clinician-delivered CBT-I.
Use of Somryst durably improves insomnia symptoms in adults with chronic insomnia who do not have contraindicated sleep, medical, and/or psychiatric disorders. Pivotal study results show that over 40% of Somryst-treated patients no longer met criteria for chronic insomnia post- treatment, and over 60% demonstrated a clinically meaningful insomnia treatment response with no adverse events reported.
With outcomes that speak for themselves, Somryst represents a promising clinical modality for the treatment of adults with chronic insomnia who are receiving standard outpatient care.
Nox aims to bring Somryst to a wider audience, starting with its existing Enterprise client base and expanding to other opportunities throughout their business. This marks a major milestone in the Nox growth journey and will further scale their future success.